MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
The molecular genetics of Barrett's esophagus (BE) and its evolution to esophageal adenocarcinoma (EAC) have been widely studied; however, the molecular mechanism of BE-EAC carcinogenesis has not been completely understood. MicroRNA (miRNA) is now essential to understand the molecular mechanism of cancer progression. Recent findings include the following: firstly, miRNA expression profiles can distinguish between BE and EAC; secondly, miR-196a is upregulated in EAC tissues targeting annexin A1, thereby exerting antiapoptotic effects and contributing to EAC cell survival; miR-196a may also constitute a good biomarker of progression during BE-EAC carcinogenesis; and thirdly, The miR-106b-25 polycistron is activated by genomic amplification and is involved in esophageal neoplastic progression and proliferation via the suppression of two target genes, p21 and Bim.
Department of Surgery, Kyoto University Hospital, Shogoin, Kyoto City, Japan. tsugu@kuhp.kyoto-u.ac.jp
Takatsugu
T
Kan
Stephen J
SJ
Meltzer
D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D001471:Barrett Esophagus / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis / Q000145:classification / Q000378:metabolism* / Q000627:therapeutic use*; D008957:Models, Genetic; D011230:Precancerous Conditions / Q000235:genetics* / Q000378:metabolism / Q000628:therapy
D035683:MicroRNAs